QuidelOrtho (NASDAQ:QDEL) Stock Rating Lowered by Zacks Research

QuidelOrtho (NASDAQ:QDEL) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research note on Wednesday, July 1st. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. Citigroup increased their price objective on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $13.62.

QuidelOrtho Trading Up 1.8%

Shares of QuidelOrtho stock opened at $15.09 on Wednesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. QuidelOrtho has a 1 year low of $9.92 and a 1 year high of $35.58. The firm has a market cap of $1.03 billion, a PE ratio of -0.98 and a beta of 0.68. The company has a 50 day simple moving average of $15.80 and a two-hundred day simple moving average of $16.99.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Analysts expect that QuidelOrtho will post 0.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On QuidelOrtho

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC lifted its position in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares during the last quarter. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho in the fourth quarter worth approximately $29,000. Hantz Financial Services Inc. increased its stake in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after buying an additional 362 shares during the period. Larson Financial Group LLC increased its stake in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after buying an additional 1,015 shares during the period. Finally, GAMMA Investing LLC raised its holdings in QuidelOrtho by 67.7% during the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock valued at $38,000 after buying an additional 882 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.